CohBar’s Abstract for the American Thoracic Society 2020 International Conference Published in the American Journal of Respiratory and Critical Care Medicine
May 01, 2020 11:00 ET
|
CohBar, Inc.
MENLO PARK, Calif., May 01, 2020 (GLOBE NEWSWIRE) -- CohBar, Inc. (NASDAQ: CWBR), a clinical stage biotechnology company developing mitochondria based therapeutics to treat chronic diseases and...
CohBar to Announce 2020 First Quarter Financial Results and Provide Business Update on May 14, 2020
April 30, 2020 09:00 ET
|
CohBar, Inc.
MENLO PARK, Calif., April 30, 2020 (GLOBE NEWSWIRE) -- CohBar, Inc. (NASDAQ: CWBR), a clinical stage biotechnology company developing mitochondria based therapeutics to treat chronic diseases and...
CohBar Announces Acceptance of Late Breaking Abstract on its Antifibrotic Peptides at The American Thoracic Society 2020 International Conference
April 14, 2020 08:30 ET
|
CohBar, Inc.
MENLO PARK, Calif., April 14, 2020 (GLOBE NEWSWIRE) -- CohBar, Inc. (NASDAQ: CWBR), a clinical stage biotechnology company developing mitochondria based therapeutics to treat chronic diseases and...
CohBar Provides Update on CB4211 Phase 1b Study for NASH and Obesity
March 30, 2020 08:45 ET
|
CohBar, Inc.
MENLO PARK, Calif., March 30, 2020 (GLOBE NEWSWIRE) -- CohBar, Inc. (NASDAQ: CWBR), a clinical stage biotechnology company developing mitochondria based therapeutics to treat chronic diseases and...
CohBar Reports Fourth Quarter 2019 Financial Results and Provides Business Update
March 12, 2020 16:02 ET
|
CohBar, Inc.
MENLO PARK, Calif., March 12, 2020 (GLOBE NEWSWIRE) -- CohBar, Inc. (NASDAQ: CWBR), a clinical stage biotechnology company developing mitochondria based therapeutics (MBTs) to treat chronic diseases...
CohBar to Hold Investor Meetings at the ROTH Virtual Conference
March 12, 2020 08:30 ET
|
CohBar, Inc.
MENLO PARK, Calif., March 12, 2020 (GLOBE NEWSWIRE) -- CohBar, Inc. (NASDAQ: CWBR), a clinical stage biotechnology company developing mitochondria based therapeutics to treat chronic diseases and...
CohBar to Announce 2019 Fourth Quarter Financial Results and Provide Business Update on March 12, 2020
March 02, 2020 16:30 ET
|
CohBar, Inc.
MENLO PARK, Calif., March 02, 2020 (GLOBE NEWSWIRE) -- CohBar, Inc. (NASDAQ: CWBR), a clinical stage biotechnology company developing mitochondria based therapeutics (MBTs) to treat chronic diseases...
CohBar to Present at the 2020 BIO CEO & Investor Conference
January 28, 2020 09:00 ET
|
CohBar, Inc.
MENLO PARK, Calif., Jan. 28, 2020 (GLOBE NEWSWIRE) -- CohBar, Inc. (NASDAQ: CWBR), a clinical stage biotechnology company developing mitochondria based therapeutics (MBTs) to treat chronic diseases...
CohBar Appoints Jordyn Tarazi as Director of Investor Relations
January 22, 2020 09:00 ET
|
CohBar, Inc.
MENLO PARK, Calif., Jan. 22, 2020 (GLOBE NEWSWIRE) -- CohBar, Inc. (NASDAQ: CWBR), a clinical stage biotechnology company developing mitochondria based therapeutics (MBTs) to treat chronic diseases...
CohBar Discovers Novel Peptide Inhibitors of CXCR4, a Key Regulator of Tumor Growth and Metastasis
January 08, 2020 09:00 ET
|
CohBar, Inc.
MENLO PARK, Calif., Jan. 08, 2020 (GLOBE NEWSWIRE) -- CohBar, Inc. (NASDAQ: CWBR), a clinical stage biotechnology company developing mitochondria based therapeutics (MBTs) to treat chronic diseases...